Neuro Advance will bring together a mix of stellar scientists, entrepreneurs and company creators to talk about the advancing frontier of neuroscience research and catalysts to progress for patients. It will be an exciting day!
Boston, MA (PRWEB) September 20, 2016
Leading CEOs, CSOs, CMOs and heads of neuroscience from top biopharmaceutical companies in the neuroscience and pain management space will join prominent academics and key investors for Neuro Advance Boston on October 5, 2016 at the Joseph B. Martin Conference Center at Harvard Medical School in Boston.
Neuro Advance Boston focuses on the latest developments and opportunities in neuroscience. The agenda meeting features luminaries in neuroscience research and development, as well as executives of leading neuro companies who will explore the most relevant issues facing neuroscience and biotechnology today. Panel topics include Novel Approaches to Alzheimer’s Disease, Advances in Orphan Diseases, Progress in Neurogaming, Genetics of Neurology & Psychiatry, Investor Perspectives on Neuroscience Drug Development and more.
“As our scientific understanding of neuroscience grows, events such as Neuro Advance Boston become powerful forums for discussion and collaboration with the goal of advancing patient care.”, says Cynthia Schwalm, EVP of Commercial Operations-North America, IPSEN.
Deborah Dunsire, CEO of Southern Cross Biotech Consulting and former CEO of Forum Pharmaceuticals continues, “Advances in the treatment of Neurological and psychiatric diseases have lagged other areas, but recently there is a resurgence in promising approaches to some of the most difficult to treat diseases. Neuro Advance will bring together a mix of stellar scientists, entrepreneurs and company creators to talk about the advancing frontier of neuroscience research and catalysts to progress for patients. It will be an exciting day!”
Additional conference speakers include: PJ Anand (CEO, Alcyone Lifesciences), Richard Brudnick (SVP, Corporate Development, Biogen), Belen Carrillo-Rivas (Global Clinical Submission Lead, Pfizer), David Elmaleh (Scientific Founder and Chairman, AZTherapies), Liam Ratcliffe (Managing Director, New Leaf Venture Partners), Cameron Wheeler (Principal, Deerfield Management), Charles Stacey (President and CEO, Accera), Robert Silverman (Head of Externalized Drug Discovery Partnering, Roche), Charles Stacey (President and CEO, Accera), Liam Ratcliffe (Managing Director, New Leaf Venture Partners), David Elmaleh (Scientific Founder and Chairman, AZTherapies), Belen Carrillo-Rivas (Global Clinical Submission Lead, Pfizer), Peter Bergethon (Interim Chief Science Officer-Neuroscience and Pain Research Unit, Pfizer), PJ Anand (CEO, Alcyone Lifesciences), Thomas Wessel (CMO, Flex Pharma), and other prominent industry leaders.
For more information or to register for the conference, visit: http://bbbiotechconference.com/conference-agenda.php?id=41
ABOUT THE BOSTON BIOTECH CONFERENCES
The Boston Biotech Conferences (BBC)’s mission is to build a vibrant community of biopharma leaders, which will help to drive biopharma innovation in biotech, by convening leaders across industry and academia. The conferences are exclusive, thought-leader forums for senior biopharma executives. Each conference is highly interactive and co-hosted by healthcare industry leaders to foster discussions and facilitate information-sharing, networking, and corporate development within the biopharma community.
The meetings are invitation-only, off-the-record forums that bring together the past, present, and future leaders in the healthcare community to network, exchange ideas and share insights into the industry's challenges and opportunities. For more information or to register, visit http://www.bbbiotechconference.com.